#United States #New York #Investor Conferences #Biopharma #Vanda Pharmaceuticals

Vanda Pharmaceuticals: Engaging with Investors This November

Vanda Pharmaceuticals Inc., a prominent name in the biopharmaceutical sector, has officially announced its participation in a series of significant investor conferences this November 2026. This is an excellent opportunity for interested parties to gain insight into the company’s strategies and future directions.

Upcoming Conferences

The company will make its presence felt at various conferences in New York City and London, known for attracting industry leaders and investors alike. Notable events include:

• - November 10, 2026: 8th Annual Wolfe Research Healthcare Conference (New York City)
• - November 11, 2026: Stifel 2026 Healthcare Conference (New York City)

- A special fireside chat is scheduled for 8:40 a.m. Eastern Time.

• - November 12, 2026: Truist Securities 2026 Biopharma Symposium (New York City)
• - November 17, 2026: UBS Global Biopharma Conference (London)
• - November 19, 2026: Jefferies Global Healthcare Conference (London)

- Another fireside chat will be held at 2:00 p.m. Greenwich Mean Time (9:00 a.m. Eastern Time).

Investors are encouraged to access these events live via Vanda's corporate website, where links under the 'Investors' tab facilitate registration and participation. It is suggested that attendees log in at least 15 minutes early to ensure a smooth experience.

Live and Archived Access

The sessions at both the Stifel and Jefferies conferences will be accessible in real-time, providing a unique platform for investors to engage directly with Vanda's executives. Additionally, recorded sessions will be available on the company's website for a duration of about 30 days following the conferences. This is an excellent opportunity for those who may not be able to attend live to catch up on the discussions and insights shared.

About Vanda Pharmaceuticals Inc.

Vanda is recognized for its commitment to the development and commercialization of innovative therapies aimed at addressing critical unmet medical needs. The company’s approach is patient-centered, focusing on advancing solutions that improve lives. For more detailed information, the public can visit Vanda Pharmaceuticals and stay updated on social media, notably on X at @vandapharma.

Conclusion

The upcoming investor conferences are expected to be pivotal points for Vanda Pharmaceuticals in showcasing their advancements and future plans in the biopharmaceutical landscape. With such an array of compelling discussions and expert insights on the table, investors and stakeholders alike are in for an informative experience. Be sure to mark your calendars and engage with Vanda’s updates as these significant dates approach.